FRC Logo
🔹
🔹
•

News

Latest Market News

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Arvinas, Inc. Stock AnalysisComprehensive stock analysis for Arvinas, Inc. (ARVN) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisARVN

Arvinas, Inc.

ARVN
Stock Price
$0.00
Updated 07:12 AM
Sign In
  • Phase 1 · Company Overview
  • Phase 2 · FRC Research
  • Phase 3 · Financial Data
  • Phase 4 · Peer Comparison
  • Phase 5 · Ownership & News
ARVN$0.00
Home🔹Stocks🔹Arvinas, Inc.

Arvinas, Inc.

ARVN•NASDAQ

Arvinas, Inc.

ARVN•NASDAQ
Mkt Cap$943.66M
Sentiment

Arvinas, Inc.

ARVN
Stock Price
$0.00
Updated 07:12 AM
Sign In
  • Phase 1 · Company Overview
  • Phase 2 · FRC Research
  • Phase 3 · Financial Data
  • Phase 4 · Peer Comparison
  • Phase 5 · Ownership & News
ARVN$0.00
Phase 1 · Company Overview
1

Step 1: Overview

What the company does, where it operates, and who runs it.

Overview for Arvinas, Inc.

Industry:Biotechnology
Sector:Healthcare
CEO:John G. Houston
Description:Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
Address:5 Science Park, New Haven, CT, US
2

Step 2: Infographics

Visual summary of the business at a glance.

Phase 2 · FRC Research
3

Step 3: Media

Videos and interviews covering the company.

Phase 3 · Financial Data
4

Step 4: Stock Data

Price chart, volume, and trading data.

ARVN Stock Price

5

Step 5: Fair Value

What FRC thinks the stock is worth vs. the current price.

6

Step 6: Financial Ratios

Profitability, returns, valuation, and leverage ratios.

7

Step 7: Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

8

Step 8: Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

9

Step 9: Financial Statements

Income statement, balance sheet, and cash flow statements.

Phase 4 · Peer Comparison
10

Step 10: Comparables

List of peer companies in the same industry.

Phase 5 · Ownership & News
12

Step 12: Institutional Ownership

Which funds and firms own the stock.

13

Step 13: Insider Trading

Recent buying and selling by company executives.

14

Step 14: Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

15

Step 15: News

Latest headlines and market coverage.

News

Latest Market News

News

Latest Market News